How is stelara administered for crohn's disease?

How is the dosing schedule structured for Crohn's disease?

Stelara is given as an initial intravenous infusion followed by subcutaneous maintenance injections. The induction dose is a single 260 mg, 390 mg, or 520 mg infusion based on body weight, delivered over at least one hour. Maintenance begins eight weeks later with a 90 mg subcutaneous injection every eight weeks.

What factors determine the weight-based intravenous dose?

Patients weighing 55 kg or less receive 260 mg. Those between 55 kg and 85 kg receive 390 mg. Patients over 85 kg receive 520 mg. This calculation ensures the starting dose aligns with body mass to achieve adequate exposure.

How do patients give the maintenance injections at home?

After the first subcutaneous dose in a clinic, patients or caregivers can self-administer the 90 mg prefilled syringe or injection pen every eight weeks. Training on proper injection technique into the abdomen or thigh is provided before home use begins.

When should a patient contact their doctor about missed doses?

If a maintenance dose is missed, it should be given as soon as remembered, then the regular eight-week schedule resumes from that point. Persistent delays or missed doses may reduce treatment effectiveness, so patients are advised to reschedule promptly.

Can treatment be paused or stopped once symptoms improve?

Stelara is intended for ongoing control of Crohn's disease. Discontinuing therapy can lead to relapse, so decisions to pause or stop are made only after discussion with the prescribing physician and consideration of disease activity.

What happens if a patient needs surgery while on Stelara?

Elective surgery is often scheduled toward the end of a dosing interval to minimize infection risk. The prescriber may adjust the schedule around the procedure, and patients should inform their care team of upcoming operations.

Are there special storage or handling requirements for the injections?

Prefilled syringes and pens must be refrigerated between 2 °C and 8 °C and protected from light. They can be kept at room temperature for up to 30 days if needed, but should never be frozen or shaken.

How does Stelara compare with other biologics used in Crohn's disease?

Unlike anti-TNF agents such as adalimumab or infliximab, Stelara targets interleukin-12 and interleukin-23. This different mechanism can benefit patients who have not responded to or cannot tolerate TNF inhibitors.

When does the patent for Stelara expire?

U.S. regulatory exclusivity for Stelara is expected to end in September 2025, after which biosimilar versions may become available. DrugPatentWatch.com tracks the current patent and exclusivity landscape.

How are biosimilars expected to affect access and pricing?

Once approved, biosimilars could lower treatment costs and expand options for patients. Actual price reductions will depend on the number of entrants, payer coverage decisions, and state substitution laws.

[1] https://www.drugpatentwatch.com/drug/stelara
[2] https://www.janssenlabels.com/package-insert/stelara-pi.pdf